Skip to content
Parakho

Vimta Labs Ltd-$

NSE VIMTALABSBSE 524394vimta.comInvestor relations

Q3 FY25, unaudited

Revenue
₹89.92 Cr
Profit after tax
₹21.50 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ3 FY25vs a year ago9M FY25
Revenue from operations89.92—249.54
Other income1.23—2.60
Total income91.15—252.14
Employee benefit expense23.37—69.75
Finance costs0.58—1.46
Depreciation & amortisation9.81—26.08
Total expenses67.23—188.17
Profit before tax23.92—63.97
Tax expense6.40—15.54
Profit after tax21.50—49.02
Total comprehensive income21.49—49.01
Earnings per share
Earnings per share, basic₹9.65₹22.07
Earnings per share, diluted₹9.56₹21.78

Q3 FY25 and 9M FY25 — unaudited, from the company’s filing with NSE. Source

Q3 FY25 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q1 FY27

Vimta Labs reported Q1 FY27 total income of INR1,129 million, up 13.7% year-on-year, with EBITDA of INR411 million and PAT of INR210 million. Management said pharma contract research and testing grew year-on-year while food testing declined due to weaker import-export sample receipts linked to global trade challenges. The company secured and onboarded its first Biologics services order during the quarter and outlined an approximately INR80 crore capex plan for FY27.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 46 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Healthcare Research, Analytics & Technology

Classification as published by BSE.

Companies also in Healthcare Research, Analytics & Technology, in alphabetical order

All 11 companies in Healthcare Research, Analytics & Technology

Page generated from filings held to 30 Sept 2026.